Multiple Myeloma
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Conference Coverage
CAR T-cell benefit in lenalidomide-refractory myeloma
“Early CAR Ts demonstrating efficacy and safety and prior lines of treatment impact survival from CAR T in myeloma. Can this also be true for...
News
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
News
Women hematologists advance MM research, give back
At the frontiers of CAR T-cell research for myeloma, women blood cancer specialists break new ground while also coaching their younger women...
News
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
Conference Coverage
Experts debate reducing ASCT for multiple myeloma
Overall survival following multidrug regimens and transplant are on par, raising questions about the best frontline therapy for multiple myeloma...
News
Motixafortide may improve MM outcomes
A new drug approval for motixafortide is currently under review by the Food and Drug Administration.
News
From Beirut to frontline hematology research
A young Lebanese-American physician scientist keeps ‘smoldering’ myeloma in his sights and a sick relative in mind.
News
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.